首页> 美国卫生研究院文献>Biophysical Journal >Physiological and Pharmacological Modulation of the Embryonic Skeletal Muscle Calcium Channel Splice Variant CaV1.1e
【2h】

Physiological and Pharmacological Modulation of the Embryonic Skeletal Muscle Calcium Channel Splice Variant CaV1.1e

机译:胚胎骨骼肌钙通道剪接变体CaV1.1e的生理和药理调节

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

CaV1.1e is the voltage-gated calcium channel splice variant of embryonic skeletal muscle. It differs from the adult CaV1.1a splice variant by the exclusion of exon 29 coding for 19 amino acids in the extracellular loop connecting transmembrane domains IVS3 and IVS4. Like the adult splice variant CaV1.1a, the embryonic CaV1.1e variant functions as voltage sensor in excitation-contraction coupling, but unlike CaV1.1a it also conducts sizable calcium currents. Consequently, physiological or pharmacological modulation of calcium currents may have a greater impact in CaV1.1e expressing muscle cells. Here, we analyzed the effects of L-type current modulators on whole-cell current properties in dysgenic (CaV1.1-null) myotubes reconstituted with either CaV1.1a or CaV1.1e. Furthermore, we examined the physiological current modulation by interactions with the ryanodine receptor using a chimeric CaV1.1e construct in which the cytoplasmic II-III loop, essential for skeletal muscle excitation-contraction coupling, has been replaced with the corresponding but nonfunctional loop from the Musca channel. Whereas the equivalent substitution in CaV1.1a had abolished the calcium currents, substitution of the II-III loop in CaV1.1e did not significantly reduce current amplitudes. This indicates that CaV1.1e is not subject to retrograde coupling with the ryanodine receptor and that the retrograde coupling mechanism in CaV1.1a operates by counteracting the limiting effects of exon 29 inclusion on the current amplitude. Pharmacologically, CaV1.1e behaves like other L-type calcium channels. Its currents are substantially increased by the calcium channel agonist Bay K 8644 and inhibited by the calcium channel blocker nifedipine in a dose-dependent manner. With an IC50 of 0.37 μM for current inhibition by nifedipine, CaV1.1e is a potential drug target for the treatment of myotonic dystrophy. It might block the excessive calcium influx resulting from the aberrant expression of the embryonic splice variant CaV1.1e in the skeletal muscles of myotonic dystrophy patients.
机译:CaV1.1e是胚胎骨骼肌的电压门控钙通道剪接变体。它与成年CaV1.1a剪接变体的区别在于,在连接跨膜结构域IVS3和IVS4的细胞外环中排除了编码19个氨基酸的29号外显子。像成年剪接变体CaV1.1a一样,胚胎CaV1.1e变体在激发-收缩耦合中充当电压传感器,但与CaV1.1a不同,它还传导可观的钙电流。因此,钙电流的生理或药理学调节可能在表达CaV1.1e的肌肉细胞中产生更大的影响。在这里,我们分析了L型电流调节剂对用CaV1.1a或CaV1.1e重构的致病性(CaV1.1-null)肌管中全细胞电流特性的影响。此外,我们研究了使用嵌合CaV1.1e构建体通过与ryanodine受体相互作用而进行的生理电流调节,其中骨骼肌兴奋-收缩偶联所必需的胞质II-I​​II环已被相应的但无功能的环取代。麝香通道。 CaV1.1a中的等效取代消除了钙电流,而CaV1.1e中II-III环的取代并没有显着降低电流幅度。这表明CaV1.1e不会与ryanodine受体进行逆向偶联,并且CaV1.1a中的逆向偶联机制通过抵消外显子29夹杂物对电流振幅的限制作用而起作用。在药理上,CaV1.1e的行为类似于其他L型钙通道。钙通道激动剂Bay K 8644会显着增加其电流,而钙通道阻滞剂硝苯地平则以剂量依赖的方式抑制其电流。 CaV1.1e对硝苯地平的电流抑制作用的IC50为0.37μM,是治疗强直性营养不良的潜在药物靶标。它可能阻止了强直性肌营养不良患者骨骼肌中胚胎剪接变体Ca V 1.1e的异常表达导致钙过多流入。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号